In the setting where tumor-specific ADCC triggering antibodies are used to promote NK cell activation, NK cells will receive a very strong activating signal which may override the inhibitory effects of KIR/NKG2A interaction with HLA class I. Several in vitro studies have explored the influence of KIR-ligand interaction and licensing status of the NK cell on the outcome of ADCC (Table 1 and Fig. 1). Here, KIR3DL1 is linked to neoplasm.